Latest news with #Kihealth
National Post
14-07-2025
- Health
- National Post
Kihealth Wins Innovation of the Year at ADA 85th Scientific Sessions for Groundbreaking Diabetes Diagnostic
Article content SAINT AUGUSTINE, Fla. — Kihealth, a leader in molecular diagnostics, today announced it has won the Innovation of the Year challenge at the American Diabetes Association's 85 th Scientific Session held in Chicago. Kihealth's pioneering liquid-biopsy test, which measures the rate of pancreatic beta‑cell death, earned top honors among five finalists for its potential to revolutionize early diabetes detection. Article content Dubbed the 'Super Bowl of diabetes innovation,' this prestigious award has firmly established Kihealth and its products in the spotlight. The honor follows a live pitch to a panel of expert judges and a global audience of clinicians, researchers, and industry leaders. In winning first place, Kihealth stood out for delivering a novel diagnostic that provides patients and clinicians with a critical early window into metabolic health – years before glucose or A1c abnormalities appear Article content Key Highlights & Immediate Impact Article content Surge in physician engagement: Following the win, Kihealth has received new contracts and strong interest from healthcare providers nationwide. Increased funding & partnerships: The recognition triggered follow-up discussions with institutional payers and wellness platforms exploring early-risk screening. Product visibility & credibility: The award signals clear validation of Kihealth's molecular assay and commitment to elevating standards of preventive care. Article content 'This is a monumental milestone,' said Jennifer Anderson, CEO of Kihealth. 'Winning ADA's Innovation of the Year at the 85th Scientific Sessions is the ultimate validation of our mission to enable earlier, more actionable insights into disease risk. It's sparked tremendous momentum—from physician interest and contract discussions to expanded visibility. We're just getting started.' Article content About Kihealth Article content Founded in 2023 in Florida, Kihealth is revolutionizing preventative diagnostics through ddPCR-based tests that detect metabolic and autoimmune disease risk years before traditional methods. Their flagship assay harnesses cell‑free DNA and epigenetic markers unique to beta cells. Kihealth's platform is designed for seamless integration into telehealth, employer wellness programs, clinical trials and clinical care pathways, bridging science and accessibility to redefine preventive health. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Kihealth Article content Article content Article content
Business Wire
14-07-2025
- Health
- Business Wire
Kihealth Wins Innovation of the Year at ADA 85th Scientific Sessions for Groundbreaking Diabetes Diagnostic
SAINT AUGUSTINE, Fla.--(BUSINESS WIRE)--Kihealth, a leader in molecular diagnostics, today announced it has won the Innovation of the Year challenge at the American Diabetes Association's 85 th Scientific Session held in Chicago. Kihealth's pioneering liquid-biopsy test, which measures the rate of pancreatic beta‑cell death, earned top honors among five finalists for its potential to revolutionize early diabetes detection. Dubbed the 'Super Bowl of diabetes innovation,' this prestigious award has firmly established Kihealth and its products in the spotlight. The honor follows a live pitch to a panel of expert judges and a global audience of clinicians, researchers, and industry leaders. In winning first place, Kihealth stood out for delivering a novel diagnostic that provides patients and clinicians with a critical early window into metabolic health – years before glucose or A1c abnormalities appear Key Highlights & Immediate Impact Surge in physician engagement: Following the win, Kihealth has received new contracts and strong interest from healthcare providers nationwide. Increased funding & partnerships: The recognition triggered follow-up discussions with institutional payers and wellness platforms exploring early-risk screening. Product visibility & credibility: The award signals clear validation of Kihealth's molecular assay and commitment to elevating standards of preventive care. 'This is a monumental milestone,' said Jennifer Anderson, CEO of Kihealth. 'Winning ADA's Innovation of the Year at the 85th Scientific Sessions is the ultimate validation of our mission to enable earlier, more actionable insights into disease risk. It's sparked tremendous momentum—from physician interest and contract discussions to expanded visibility. We're just getting started.' About Kihealth Founded in 2023 in Florida, Kihealth is revolutionizing preventative diagnostics through ddPCR-based tests that detect metabolic and autoimmune disease risk years before traditional methods. Their flagship assay harnesses cell‑free DNA and epigenetic markers unique to beta cells. Kihealth's platform is designed for seamless integration into telehealth, employer wellness programs, clinical trials and clinical care pathways, bridging science and accessibility to redefine preventive health. About the ADA Innovation Challenge The ADA's Innovation Challenge is an annual competition held during the Scientific Sessions. Startups pitch cutting-edge solutions before a panel of expert judges and a global healthcare audience. In its fifth year, the 2025 challenge recognized Kihealth, MYNERVA, and Kayothera for their contributions to transforming diabetes care.
Associated Press
22-06-2025
- Health
- Associated Press
The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care
This challenge Kickstarts additional investments through the new ADA Innovation Fund CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its 85th anniversary, it continues to fuel transformative progress in the fight to end diabetes—and increasingly, obesity. This year's Innovation Challenge, held during the ADA's 85th Scientific Sessions, highlighted bold ideas driving the future of diabetes treatment and support. Five visionary finalists presented their innovations on the main stage before a panel of expert judges and a live audience. Three outstanding winners were selected for their potential to revolutionize diabetes care: Kihealth, MYNERVA, and Kayothera, INC. 'One of the biggest things we've learned in our 85 years is that in the fight to end diabetes, every new bit of knowledge, every advancement in treatment, every novel idea matters. We're proud to support these innovators as they help shape a future free of diabetes and all its burdens,' said Elle Uh, the ADA's chief strategy officer and chief of staff. This year's winners and finalists included: Winner: Kihealth—A diagnostic test to measure the rate of beta cell death through a liquid biopsy, providing patients and clinicians with a clear view of metabolic health and an earlier window into disease development. Winner: MYNERVA—An AI-driven neuroprosthetic smart sock for diabetes-related neuropathy to reduce pain and regain stability. Winner: Kayothera, INC—A first-in-class antagonist of the undruggable retinoid pathway to treat and potentially reverse type 2 diabetes. Finalist: BioDynamik, Inc.—An orthopedic-driven angiogenesis to restore perfusion for the healing of recalcitrant ischemic ulcers. Finalist: Generated Health—A chatbot combining AI-driven automation and human-like empathy with a simple text-based platform designed to support both patients and health care teams. The Innovation Challenge occurs at a critical time. Over 38 million Americans live with diabetes and about 125 million live with obesity. To meet these interconnected epidemics head-on, the ADA is launching the ADA Innovation Fund, a venture philanthropy fund designed to advance the ADA's mission by investing in innovative, high-impact companies developing diabetes, obesity, and other comorbidity-related solutions. Leveraging the ADA's 85-year history of funding hundreds of millions of dollars in innovative research grants, these investments aim to continue to accelerate mission-critical scientific breakthroughs, reduce health disparities, and promote sustainable health care solutions. About the ADA's Scientific Sessions The ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook ( American Diabetes Association ), Spanish Facebook ( Asociación Americana de la Diabetes ), LinkedIn ( American Diabetes Association ), and Instagram ( @AmDiabetesAssn ). To learn more about how we are advocating for everyone affected by diabetes, visit us on X ( @AmDiabetesAssn ). View original content to download multimedia: SOURCE American Diabetes Association
